NIH-funded research R01 grant

Atrial fibrillation, clots, and stroke: the heart’s JNK2 as a target

Official title: Atrial fibrillation, Thrombogenesis, and Stroke: the central role of JNK2 with therapeutic potentials

Funded at Ohio State University · NIH-11465511 · Data updated 2026-11-12

This NIH grant explores how a heart protein called JNK2 may drive atrial fibrillation, blood clots, and stroke, and whether it could serve as a biomarker and new treatment approach.

More Stroke research and trials

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionOhio State University
NIH-funded
Lab location1 site (Columbus, UNITED STATES)
Project startMay 15, 2019
Project endApril 30, 2030
Funding year2026
Award (this year)$807,274
NIH project number2R01HL146744-05
Project IDNIH-11465511 on NIH RePORTER

Who could benefit from this research

Could help

Adults with atrial fibrillation or high stroke risk who may donate blood or tissue samples and participate in related biomarker studies.

Less likely to help

People without AF or stroke risk factors may not directly benefit.

What this research studies

If you have atrial fibrillation or are at risk for stroke, this research looks at how JNK2 in the heart influences blood clotting and stroke risk. The project builds on prior findings showing that JNK2 activity can travel in particles from the heart and make platelets more likely to form clots, potentially leading to stroke. Researchers will study the biological mechanisms in animal models and human cells, and test whether targeting JNK2 could both predict risk and reduce clotting. The goal is to identify new ways to prevent stroke in people with AF or similar conditions, especially as aging raises risk. This work could translate into better-guided therapies for preventing embolic events in patients with AF.

Why it matters

Potential benefit: If successful, the work could lead to new biomarkers and therapies that reduce stroke risk for people with atrial fibrillation.

How similar studies have gone: Preliminary human platelet studies and animal models support the approach, suggesting a promising direction but not yet proven in patients.

Where this research is happening

  • Ohio State University
    Columbus, United States
    Active

Researchers

  • Principal investigator: Ai, Xun — Ohio State University
  • Study coordinator: Ai, Xun

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.